Ind-Swift Limited (BOM: 524652)

Market Cap	1.57B
Revenue (ttm)	4.88B
Net Income (ttm)	549.25M
Shares Out	54.16M
EPS (ttm)	10.14
PE Ratio	2.86
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,599
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	15.19 - 32.49
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 11, 2025

About Ind-Swift

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicine...

• Industry: Pharmaceutical Preparations
• Founded: 1983
• Employees: 1,054
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524652

Financial Performance

In 2023, Ind-Swift's revenue was 5.02 billion, an increase of 22.22% compared to the previous year's 4.11 billion. Earnings were 142.31 million, a decrease of -45.34%.